Evaluation of quality of life in patients with narcolepsy treated with sodium oxybate : use of the 36-item short-form health survey in a clinical trial
dc.contributor.author | Bogan, Richard | |
dc.contributor.author | Swick, Todd | |
dc.contributor.author | Mamelak, Mortimer | |
dc.contributor.author | Kovacevic-Ristanovic, Ruzica | |
dc.contributor.author | Lai, Chinglin | |
dc.contributor.author | Black, Jed | |
dc.contributor.author | Villa, Kathleen F. | |
dc.contributor.author | Montplaisir, Jacques-Yves | |
dc.date.accessioned | 2020-06-09T15:56:37Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2020-06-09T15:56:37Z | |
dc.date.issued | 2016-10-24 | |
dc.identifier.uri | http://hdl.handle.net/1866/23449 | |
dc.publisher | Springer | fr |
dc.subject | Narcolepsy | fr |
dc.subject | Sodium oxybate | fr |
dc.subject | Quality of life | fr |
dc.subject | SF-36 | fr |
dc.title | Evaluation of quality of life in patients with narcolepsy treated with sodium oxybate : use of the 36-item short-form health survey in a clinical trial | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine. Département de psychiatrie et d'addictologie | fr |
dc.identifier.doi | 10.1007/s40120-016-0053-5 | |
dcterms.abstract | Introduction The present post hoc analysis was designed to evaluate health-related quality of life (HRQoL) using the 36-item Short Form Health Status Survey (SF-36) during an 8-week trial of sodium oxybate (SXB). Methods SF-36 was assessed in a phase 3 placebo-controlled trial in patients with narcolepsy (N = 228) randomized to placebo or SXB in doses of 4.5, 6, or 9 g nightly for 8 weeks. Changes from baseline in SF-36 (last observation carried forward) were compared between SXB and placebo, and effect sizes (ES) were estimated. Results Baseline SF-36 values were lower than normative values for the US general population. After 8 weeks of treatment, mean (±standard deviation) improvement from baseline on the Physical Component Summary (PCS) was significantly greater with SXB 9 g/night than placebo (6.3 ± 9.1 vs. 1.5 ± 6.2; p = 0.005), with moderate ES; no significant difference was found between the SXB and placebo groups on the Mental Component Summary. SXB 9 g/night resulted in significantly (p < 0.05) greater improvements than placebo in Physical Functioning (4.4 ± 9.2 vs. 1.0 ± 8.0), General Health (GH; 3.1 ± 7.0 vs. 0.4 ± 6.8), and Social Functioning (6.8 ± 16.8 vs. 1.1 ± 9.6). All SXB doses resulted in significant improvement (p < 0.05) relative to placebo for Vitality, with moderate ES. No significant differences versus placebo were observed for Role–Physical, Role–Emotional, or Mental Health domains. Conclusion Treatment with SXB was associated with a dose-dependent improvement in HRQoL, with the 9-g nightly dose demonstrating a positive impact on PCS and individual SF-36 domains of Vitality, GH, and Physical and Social Functioning. | fr |
dcterms.isPartOf | urn:ISSN:2193-8253 | fr |
dcterms.isPartOf | urn:ISSN:2193-6536 | fr |
dcterms.language | eng | fr |
UdeM.ReferenceFournieParDeposant | Bogan, R., Swick, T., Mamelak, M., Kovacevic-Ristanovic, R., Lai, C., Black, J., ... & Montplaisir, J. (2016). Evaluation of quality of life in patients with narcolepsy treated with sodium oxybate: use of the 36-item short-form health survey in a clinical trial. Neurology and therapy, 5(2), 203-213. | fr |
UdeM.VersionRioxx | Version originale de l'auteur·e / Author's Original | fr |
oaire.citationTitle | Neurology and therapy | |
oaire.citationVolume | 5 | |
oaire.citationIssue | 2 | |
oaire.citationStartPage | 203 | |
oaire.citationEndPage | 213 |
Fichier·s constituant ce document
Ce document figure dans la ou les collections suivantes
Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Il peut être utilisé dans le cadre d'une utilisation équitable et non commerciale, à des fins d'étude privée ou de recherche, de critique ou de compte-rendu comme le prévoit la Loi. Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.